Today Stories

LEIDEN, The Netherlands, November 02, 2022 / B3C newswire / -- MIMETAS is the winner of the Dutch Innovation Award 2022. This award recognizes the company's considerable focus on innovation, contribution to the reduction of animal experimentation, leadership, organization, cooperation with partners, and market position. Henk Volberda, chairman of the jury and professor of Strategy & Innovation at the University of Amsterdam: “MIMETAS is world-leading. Since its foundation in 2013, the company has grown considerably, with branches in Europe, the USA, and Asia. It can now count the largest pharmaceutical companies worldwide among its partners. With its miniaturized organs-on-a-chip, MIMETAS has found a promising approach to enable major advancements in the pharmaceutical industry.” “The…

Strengthens Johnson & Johnson’s MedTech Business with the Addition of Abiomed, a World-Leader in Heart RecoveryTransaction to Bring Lifesaving Innovations to More Patients with Unmet NeedExpected to Enhance Johnson & Johnson’s Near- and Long-Term Sales and Earnings Growth; Accretive to Adjusted Earnings beginning in 2024Conference Call at 8:00 a.m. ET To Discuss Details of the Transaction New Brunswick, N.J. and Danvers, Mass., November 1, 2022 – Johnson & Johnson (NYSE: JNJ), the world’s largest, most diversified healthcare products company, and Abiomed (NASDAQ: ABMD), a world leader in breakthrough heart, lung and kidney support technologies, today announced that they have entered into a definitive agreement under which Johnson & Johnson will acquire through a tender o…

– Leaders in biotech and genomics to launch more personalised genomic solutions to more than 10,000 people across the Baltics and Mediterranean regions – L’AQUILA, Italy, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Biotechnology startup Longenesis has partnered with Dante Genomics, a global leader in genomics and precision medicine, to offer whole genome sequencing (WGS) to more than 10,000 existing Longenesis study participants. WGS and Dante’s subsequent genomic reports are valuable health tools that can provide physicians and individuals with information about personalised dietary choices, predisposition to genetic diseases, genetic carrier information and more. Traditionally, DNA tests have been limited in the Baltic and Mediterranean regions due to cost and availability of practitioners, servic…

Expands Specialty Diagnostics Segment with Industry Leader in Oncology Testing for Detection and Monitoring of Multiple Myeloma Complements Existing Specialty Diagnostics Offering with Established Technologies Delivering Strong Clinical Value for Patients in a Rapidly Growing Diagnostics Segment WALTHAM, Mass.--(BUSINESS WIRE)-- Thermo Fisher Scientific Inc. (NYSE: TMO) (“Thermo Fisher”), the world leader in serving science, today announced that it has entered into a definitive agreement to acquire The Binding Site Group (“The Binding Site”), a global leader in specialty diagnostics, from a shareholder group led by European private equity firm Nordic Capital, in an all-cash transaction valued at £2.25 billion, or $2.6 billion at current exchange rates. Serving clinicians and laboratory pro…

– Genomic Biopharma Inc. to present abstracts on two drug candidate programs at the 2022 American Society of Human Genetics (ASHG) Annual Meeting – NEW YORK, Oct. 26, 2022 (GLOBE NEWSWIRE) -- Dante Genomics, a global leader in genomics and precision medicine, today announced the creation of Genomic Biopharma Inc., a separate drug discovery and development company to distinguish the separate business streams of each entity. Genomic Biopharma Inc. will present two abstracts on two drug programs at the 2022 American Society of Human Genetics (ASHG) Annual Meeting, the first of which is a top scoring abstract at the meeting titled: Abstract Title: A computational approach to design a COVID-19 vaccine against a predicted SARS-CoV-2 variant: high immunogenicity, efficacy and safety of DELLERA v…

GENERATION OF LONGITUDINAL PANOMICS DATA TO IMPROVE THE DISEASE UNDERSTANDING OF SJÖGREN’S SYNDROME (“SJS”) AND SYSTEMIC LUPUS ERYTHEMATOSUS (“SLE”) HANNOVER MEDICAL SCHOOL (“MHH”) WILL COLLECT BIOSAMPLES FROM SJS AND SLE PATIENTS EVOTEC WILL LEVERAGE ITS UNIQUE PANOMICS TECHNOLOGIES TO IMPROVE PATIENT STRATIFICATION AND CREATE NEW ENTRY POINTS FOR PRECISION MEDICINE DRUG DISCOVERY Hamburg, Germany, 25 October 2022:Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) announced today that the Company has entered a partnership with Hannover Medical School (“MHH”), one of the leading German universities, to generate a molecular patient database for Sjögren’s syndrome (“SjS”) and systemic lupus erythematosus (“SLE”).The strategic partnership between Evotec…

Also known as a form of blood cancer, Myelodysplastic syndromes (MDS) are an often unrecognised, under-diagnosed rare group of bone marrow failure disorders, where the body no longer makes enough healthy, normal blood cells in the bone marrow. There are many different types of MDS, with some types staying mild for years and others becoming more serious. Although MDS can affect people of any age, it is most common in adults over the age of 60. MDS World Awareness Day Every year on October 25th, the MDS Alliance and member groups across the world come together to raise awareness of MDS. This year, the Alliance is sharing information on the signs and symptoms of MDS and highlighting the importance of getting a blood test with a full blood count analysis to confirm a diagnosis. The four main…

Leicester-based procurement services organisation Unimed Procurement Services (Unimed) has joined forces with International Health Partners (IHP) to create a long-lasting partnership dedicated to supplying life-saving medical supplies to countries in need. In line with the two organisations’ mutual objective to increase accessibility to essential medical products and supplies to countries that are unable to access basic resources, the ongoing partnership involves several shipments of a variety of products donated by Unimed, a contribution worth $69,000. As the largest coordinator of donated medical products in the UK and Europe, IHP works with a strong network of global healthcare industry donors, and will coordinate the placement and safe transport of the products to their in-country NGO…

-- DJS Antibodies' DJS-002 is a potential first-in-class antibody directed to LPAR1, currently in investigational preclinical studies for the treatment of Idiopathic Pulmonary Fibrosis and other fibrotic diseases -- The company's proprietary HEPTAD platform will extend AbbVie's current discovery research capabilities by generating potential novel antibodies against difficult-to-drug protein targets in immunology and beyond NORTH CHICAGO, Ill., Oct. 20, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the acquisition of DJS Antibodies Ltd ("DJS"), a privately-held UK-based biotechnology company dedicated to discovering and developing antibody medicines that target difficult-to-drug disease-causing proteins, such as G protein-coupled receptors (GPCRs). DJS's lead program is DJS-002,…

Tübingen and Ingelheim, Germany, 20 October 2022 – University of Tübingen, a leading member of Cyber Valley, Europe’s largest Artificial Intelligence (AI) research consortium and Boehringer Ingelheim launch an AI and data science fellowship program for top talents from around the world. Three to five fellowships will be awarded per year for up to three years with a target of nine to fifteen fellows in the program after five years. The partners will define cutting-edge research topics at the intersection of health and applications of AI, which will be selected by a joint steering committee. First fellowships have been published here and interested post-doctoral candidates are invited to submit their applications. Jan Nygaard Jensen, Global Head of Computational Biology and Digital Sciences…

Proposed acquisition will accelerate gene therapies that aim to restore, improve, and preserve hearing for patients living with disabling hearing loss worldwide Transaction valued at approximately $487 million plus a contingent value right for an aggregate amount up to approximately $610 million INDIANAPOLIS and BOSTON, Oct. 18, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Akouos, Inc. (NASDAQ: AKUS) today announced a definitive agreement for Lilly to acquire Akouos, a precision genetic medicine company that is developing a portfolio of first-in-class adeno-associated viral gene therapies for the treatment of inner ear conditions, including sensorineural hearing loss. "We are honored to work with the talented team at Akouos who are breaking new ground in the science of trea…

Collaboration leverages one of world’s largest sources of de-identified patient data to accelerate drug discovery, initially in oncology Access will enable GSK to improve clinical trial design, speed up enrolment and identify drug targets GSK plc (LSE/NYSE: GSK) and Tempus, a US-based precision medicine company, have entered into a three-year collaboration agreement that provides GSK with access to Tempus’ AI-enabled platform, including its library of de-identified patient data. Through its leading Artificial Intelligence and Machine Learning (AI/ML) capability, GSK will work together with Tempus to improve clinical trial design, speed up enrolment and identify drug targets. This will contribute to GSK’s R&D success rate and provide patients with more personalised treatment faste…

– Gilead Granted Exclusive Option to License MGD024, a Phase 1 CD123×CD3 DART® Molecule with Potential to Treat Various Hematologic Malignancies – – Potential for Companies to Collaborate on Two Additional Future Research Programs – FOSTER CITY, Calif. & ROCKVILLE, Md.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (NASDAQ: GILD) and MacroGenics (NASDAQ: MGNX) today announced an exclusive option and collaboration agreement to develop MGD024, an investigational, bispecific antibody that binds CD123 and CD3 using MacroGenics’ DART® platform, and two additional bispecific research programs. The collaboration agreement grants Gilead the option to license MGD024, a potential treatment for certain blood cancers, including acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). This press…

Agreement key to building pan-European market access practice while underscoring a think global, act local commitment   Frankfurt, Germany – 13 October 2022: PharmaLex Group, the leading provider of specialised services for the pharma, biotech and MedTech industries worldwide, has announced a merger with UK pharmaceutical and healthcare services consultancy, NeoHealthHub Limited.  The agreement with NeoHealthHub (NHH), which was signed on Monday 10 October and which closes at the end of October,  will be an important step in building a pan-European market access practice covering major markets, including the UK, Germany, Italy, Spain, France and the Nordics.   Founded in 2013, NHH supports its customers by offering innovative and comprehensive market access,  data and capability developmen…

$97 million investment enhances bioanalytical services, helping pharma and biotech customers accelerate drug development WILMINGTON, N.C.--(BUSINESS WIRE)-- Thermo Fisher Scientific, the world leader in serving science, today expanded its clinical research operations with the opening of a state-of-the art bioanalytical lab in Richmond, Virginia. The new unit will support increasing demand across biopharma for consistent, high-quality laboratory services to accelerate drug development. The 59,000-square-foot facility is part of the previously announced $97 million investment by the company to expand its bioanalytical laboratory operations in Richmond and add more than 500 jobs over the next three years. The current laboratory services operation in Richmond, which Thermo Fisher acquired thro…

Collaboration Streamlines Clinical Trial Tokenization, Further Empowers Medical Affairs, Market Access, HEOR and Commercial Analytics for Clients   MORRISVILLE, N.C. – October 11, 2022 – Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced an expanded partnership with Datavant, the leader in helping organizations securely connect health data. The increasing collaboration between the companies will further leverage the full suite of capabilities in Datavant Switchboard and Datavant’s large data ecosystem to accelerate the clinical development and commercialization of new therapies for patients.   Syneos Health and Datavant have a long-standing strategic partnership, and through this expanded relationship, Syneos Health will use Da…

RAHWAY, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside the United States and Canada, has been named to Fortune’s 2022 Change the World list. The annual list recognizes companies that have had a positive social impact through activities that are part of their core business strategy. Merck was selected for its work expanding global access to the company’s human papillomavirus (HPV) vaccines. “It’s an honor for Merck to be included on Fortune’s 2022 Change the World List, and recognized for making our HPV vaccines available to communities around the world,” said Robert M. Davis, chief executive officer and president, Merck. “This is the third time over the last five years that our company has been on this list and we are very proud of being acknowledged for the positive impac…

Leicester-based procurement services organisation Unimed Procurement Services (Unimed) has joined forces with International Health Partners (IHP) to create a long-lasting partnership dedicated to supplying life-saving medical supplies to countries in need. In line with the two organisations’ mutual objective to increase accessibility to essential medical products and supplies to countries that are unable to access basic resources, the ongoing partnership involves several shipments of a variety of products donated by Unimed, a contribution worth $69,000. As the largest coordinator of donated medical products in the UK and Europe, IHP works with a strong network of global healthcare industry donors, and will coordinate the placement and safe transport of the products to their in-country NGO…

Acquisition adds breakthrough calcitonin gene-related peptide portfolio, including NURTEC® ODT, to address needs of millions of migraine patients worldwide NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) announced today the completion of its acquisition of Biohaven Pharmaceutical Holding Company Ltd., the maker of NURTEC® ODT (rimegepant), an innovative migraine therapy approved for both acute treatment and prevention of episodic migraine in adults. The acquisition brings to Pfizer a portfolio of promising calcitonin gene-related peptide (CGRP) receptor antagonists including: Rimegepant: Approved in the United States under the trade name NURTEC® ODT, in adults for both the acute treatment of migraine with or without aura and the preventive treatment of episodic migraine Approved in t…

BURLINGTON, N.C.--(BUSINESS WIRE)--Oct. 3, 2022-- Labcorp (NYSE: LH), a leading global life sciences company, today announced the completion of transactions that establish a long-term laboratory relationship with Ascension, one of the leading non-profit and Catholic health systems in the United States. “Today’s announcement marks the beginning of an exciting chapter for both organizations, and for the patients, communities and clinicians we serve,” said Dr. Brian Caveney, chief medical officer and president of Labcorp Diagnostics. “We welcome those Ascension associates who will join Labcorp as a part of this strategic collaboration and look forward to working together to provide a smooth transition for patients, clinicians and employees.” As a part of the companies’ strategic collaboration…